KMDA Stock Chart & Stats
$8.63
-$0.07(-0.99%)
At close: 4:00 PM EDT
$8.63
-$0.07(-0.99%)
Day’s Range― - ―
52-Week Range$6.50 - $9.35
Previous Close$6.99
Volume37.86K
Average Volume (3M)50.17K
Market Cap
$482.11M
Enterprise Value$1.09K
Total Cash (Recent Filing)$69.66M
Total Debt (Recent Filing)$11.72M
Price to Earnings (P/E)21.5
Beta0.54
Next Earnings
Nov 16, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield5.07%
Share Statistics
EPS (TTM)0.38
Shares Outstanding57,694,270
10 Day Avg. Volume69,888
30 Day Avg. Volume50,171
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside62.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$684.30K
Bulls Say, Bears Say
Bulls Say
Improved Profitability And Cash GenerationKamada is converting stronger demand into improving earnings and operating cash flow. Sustained EBITDA margins and higher cash generation provide resources to fund manufacturing, commercial expansion and pipeline activity.
Conservative Balance SheetVery low leverage and substantial liquidity reduce refinancing risk and give Kamada flexibility to invest in capacity, pursue partnerships or acquisitions, and absorb volatility typical of plasma supply and biologics manufacturing.
Long-Term Commercial ExpansionThe multiyear plasma agreement validates collection investments and adds contracted commercial visibility, while biosimilar launches and new distribution agreements broaden the portfolio and geographic reach beyond existing products.
Bears Say
Cooling Revenue GrowthAlthough recent quarterly growth was strong, the broader trend shows a marked slowdown from earlier expansion. Sustaining growth may require successful biosimilar launches, further distribution gains or acquisitions.
Gross Margin Mix PressureProduct and geographic mix changes can make profitability less predictable and may constrain margin expansion. Without demonstrated improvement from vertical integration, future growth may not translate proportionally into earnings.
Constrained Plasma CapacityCommitted capacity supports contracted revenue but reduces flexibility to capture additional customers or respond to demand elsewhere. This may limit near-term manufacturing scalability and increase dependence on execution under one agreement.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $6.50 and its highest was $9.35 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $482.11M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Nov 16, 2026 which is in 77 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Aug 12, 2026. The company reported $0.172 earnings per share for the quarter, beating the consensus estimate of $0.112 by $0.06.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of $0.17 which represents an annual dividend yield of 5.07%. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.13.
How many shares outstanding does Kamada have?
Kamada has 57,694,270 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.172 in its last earnings report, beating expectations of $0.112. Following the earnings report the stock price went down -2.966%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (62.22% Upside)
$14.00 (62.22% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
5.07%
Trailing 12-Months
Asset Growth
2.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kamada
Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
KMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: management reported record revenues, strong adjusted EBITDA and margins, sizable operating cash flow improvement, and secured a meaningful $50M plasma supply agreement while expanding distribution and biosimilar initiatives. Notable risks and concerns include a quarter-to-quarter gross profit shift due to product mix, a planned CFO departure, modest decline in cash after a dividend, and management's decision not to raise guidance despite strong H1 results. Overall, the positive financial momentum and strategic commercial wins outweigh the limited operational and corporate governance headwinds.View all KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
$14.00
▲(62.22% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.44% Mutual Funds
4.30% Other Institutional Investors
93.95% Public Companies and
Individual Investors